Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis

Overview

Journal J Allergy Clin Immunol Pract

Specialty Allergy & Immunology

Date 2023 Mar 23

PMID 36958519

Authors

Melanie C Dispenza

Dean D Metcalfe

Ana Olivera

Affiliations

Soon will be listed here.

Abstract

Anaphylaxis is an acute, potentially life-threatening systemic allergic reaction for which there are no known reliable preventative therapies. Its primary cell mediator, the mast cell, has several pathophysiologic roles and functions in IgE-mediated reactions that continue to be poorly understood. Recent advances in the understanding of allergic mechanisms have identified novel targets for inhibiting mast cell function and activation. The prevention of anaphylaxis is within reach with new drugs that could modulate immune tolerance, mast cell proliferation and differentiation, and IgE regulation and production. Several US Food and Drug Administration-approved drugs for chronic urticaria, mastocytosis, and cancer are also being repurposed to prevent anaphylaxis. New therapeutics have not only shown promise in potential efficacy for preventing IgE-mediated reactions, but in some cases, they are able to inform us about mast cell mechanisms in vivo. This review summarizes the most recent advances in the treatment of anaphylaxis that have arisen from new pharmacologic tools and our current understanding of mast cell biology.

Citing Articles

The Etiology of IgE-Mediated Food Allergy: Potential Therapeutics and Challenges.

Carnazza M, Werner R, Tiwari R, Geliebter J, Li X, Yang N Int J Mol Sci. 2025; 26(4).

PMID: 40004029 PMC: 11855496. DOI: 10.3390/ijms26041563.

Mast cells: key players in digestive system tumors and their interactions with immune cells.

Shu F, Yu J, Liu Y, Wang F, Gou G, Wen M Cell Death Discov. 2025; 11(1):8.

PMID: 39814702 PMC: 11735678. DOI: 10.1038/s41420-024-02258-y.

Mast cells: a double-edged sword in inflammation and fibrosis.

Wang X, Zhang P, Tang Y, Chen Y, Zhou E, Gao K Front Cell Dev Biol. 2024; 12:1466491.

PMID: 39355120 PMC: 11442368. DOI: 10.3389/fcell.2024.1466491.

Modulation of the Mas-Related G Protein-Coupled Receptor X2 (MRGPRX2) by Xenobiotic Compounds and Its Relevance to Human Diseases.

Dziadowiec A, Popiolek I, Kwitniewski M, Porebski G J Xenobiot. 2024; 14(1):380-403.

PMID: 38535499 PMC: 10971035. DOI: 10.3390/jox14010024.

Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.

Sabato V, Beyens M, Toscano A, Van Gasse A, Ebo D Curr Allergy Asthma Rep. 2024; 24(2):63-71.

PMID: 38217824 DOI: 10.1007/s11882-023-01123-9.

References

Polivka L, Parietti V, Bruneau J, Soucie E, Madrange M, Bayard E . The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. Blood. 2021; 138(23):2396-2407. DOI: 10.1182/blood.2020010207. View

Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, Forrer P . Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014; 133(6):1709-19.e8. PMC: 4083100. DOI: 10.1016/j.jaci.2014.02.005. View

Smiljkovic D, Herrmann H, Sadovnik I, Gamperl S, Berger D, Stefanzl G . Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils. J Allergy Clin Immunol. 2022; 151(1):202-211. DOI: 10.1016/j.jaci.2022.07.018. View

MacGlashan Jr D, Bochner B, Adelman D, Jardieu P, Togias A, McKenzie-White J . Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158(3):1438-45. View

Alvarez-Perea A, Tanno L, Baeza M . How to manage anaphylaxis in primary care. Clin Transl Allergy. 2017; 7:45. PMC: 5724339. DOI: 10.1186/s13601-017-0182-7. View

McNeil B . MRGPRX2 and Adverse Drug Reactions. Front Immunol. 2021; 12:676354. PMC: 8377365. DOI: 10.3389/fimmu.2021.676354. View

Cemerski S, Chu S, Moore G, Muchhal U, Desjarlais J, Szymkowski D . Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb. Immunol Lett. 2012; 143(1):34-43. DOI: 10.1016/j.imlet.2012.01.008. View

Leung D, Sampson H, Yunginger J, Burks Jr A, Schneider L, Wortel C . Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003; 348(11):986-93. DOI: 10.1056/NEJMoa022613. View

Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B . Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clin Transl Allergy. 2021; 11(4):e12038. PMC: 8175040. DOI: 10.1002/clt2.12038. View

10.

Tkaczyk C, Horejsi V, Iwaki S, Draber P, Samelson L, Satterthwaite A . NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. Blood. 2004; 104(1):207-14. DOI: 10.1182/blood-2003-08-2769. View

11.

Altrichter S, Staubach P, Pasha M, Singh B, Chang A, Bernstein J . An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol. 2021; 149(5):1683-1690.e7. DOI: 10.1016/j.jaci.2021.12.772. View

12.

Gilfillan A, Rivera J . The tyrosine kinase network regulating mast cell activation. Immunol Rev. 2009; 228(1):149-69. PMC: 2669301. DOI: 10.1111/j.1600-065X.2008.00742.x. View

13.

Caminati M, Olivieri E, Nalin F, Zanotti R, Senna G, Schiappoli M . Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series. Eur J Intern Med. 2019; 71:104-106. DOI: 10.1016/j.ejim.2019.11.010. View

14.

Gasser P, Tarchevskaya S, Guntern P, Brigger D, Ruppli R, Zbaren N . The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020; 11(1):165. PMC: 6949303. DOI: 10.1038/s41467-019-13815-w. View

15.

Smiljkovic D, Blatt K, Stefanzl G, Dorofeeva Y, Skrabs C, Focke-Tejkl M . BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. Allergy. 2017; 72(11):1666-1676. PMC: 5655929. DOI: 10.1111/all.13166. View

16.

Chen G, Shrock E, Li M, Spergel J, Nadeau K, Pongracic J . High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy. Cell Rep Med. 2021; 2(10):100410. PMC: 8563412. DOI: 10.1016/j.xcrm.2021.100410. View

17.

Mendez-Enriquez E, Hallgren J . Mast Cells and Their Progenitors in Allergic Asthma. Front Immunol. 2019; 10:821. PMC: 6548814. DOI: 10.3389/fimmu.2019.00821. View

18.

Sutton B, Davies A . Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. Immunol Rev. 2015; 268(1):222-35. DOI: 10.1111/imr.12340. View

19.

Lieberman P, Umetsu D, Carrigan G, Rahmaoui A . Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study. J Allergy Clin Immunol. 2016; 138(3):913-915.e2. DOI: 10.1016/j.jaci.2016.03.030. View

20.

Atanasio A, Franklin M, Kamat V, Romero Hernandez A, Badithe A, Ben L . Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response. J Allergy Clin Immunol. 2021; 149(1):200-211. DOI: 10.1016/j.jaci.2021.05.038. View